Stifel cuts IDEX stock price target to $192, keeps buy rating

On Monday, Stifel analysts adjusted their outlook on IDEX Corp (NYSE:IEX), reducing the price target to $192 from the previous $256 while reaffirming a Buy rating on the stock. The revision comes as IDEX’s shares trade at $168.51, down about 19% year-to-date. The revision reflects expectations of a mild industrial recession in the United States, anticipated to occur in the second half of 2025 through the first half of 2026, influenced by current U.S. trade policies. According to InvestingPro, IDEX maintains a GOOD financial health score, with liquid assets exceeding short-term obligations.

Stifel’s analysis suggests that the looming recession may lead to decreased capital and operating expenditures among IDEX’s customer base. The firm anticipates that the uncertain economic climate could result in more conservative spending patterns, which would impact IDEX’s performance.

Additionally, the analysts at Stifel have raised concerns about potential supply chain disruptions. These disruptions could further complicate the situation for IDEX and its customers, potentially causing a slowdown in production. The impact of such supply chain issues is factored into the revised price target.

Despite the lowered price target, Stifel continues to see value in IDEX shares, maintaining a positive Buy rating. This indicates that the firm believes IDEX stock still holds potential for investors, even considering the predicted industrial downturn and its possible effects on the company’s financial health.

The new price target of $192 represents a significant adjustment from the previous target but serves as an indicator of Stifel’s measured confidence in the company’s ability to navigate through upcoming economic challenges. The Buy rating suggests that, in Stifel’s view, IDEX’s stock may still be a worthwhile investment for those looking to add to their portfolio.

In other recent news, Ideanomics has completed the sale of nearly all its assets following a Chapter 11 bankruptcy filing. The transaction, authorized by a court order, resulted in the departure of key executives, including Shane McMahon and Ryan Jenkins. The sale proceeds were used to settle obligations under a debtor-in-possession loan agreement, leaving no distribution for shareholders. This marks a significant restructuring phase for Ideanomics as it winds down operations and transitions management.

Meanwhile, IDEX Corp has been the focus of several analyst updates. Stifel reiterated a Buy rating with a $256 price target, highlighting IDEX’s strategic shift towards growth-driven strategies. DA Davidson, however, reduced its price target to $215 while maintaining a Neutral rating, citing a weaker-than-expected organic sales forecast. RBC Capital also lowered its price target to $245 but maintained an Outperform rating, noting positive factors such as substantial incremental margins and an impressive free cash flow conversion rate.

Additionally, Citi adjusted its price target for IDEX to $264, keeping a Buy rating despite near-term underperformance. Citi acknowledged pressures on IDEX’s first-quarter outlook but noted growth in orders and demand within the Health & Science Technologies segment. These recent developments reflect a mixed outlook for IDEX, with analysts recognizing both challenges and potential for long-term growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.